Professor Hardev Pandha

Professor of Medical Oncology

Qualifications: MD PhD

Email:
Phone: Work: 01483 68 8602
Room no: 26 PGM 02

Office hours

Mon-Fri 9am-5pm.

Further information

Biography

 

MB ChB (Birm), FRACP, FRCP, PhD, CSST (Medical Oncology)

Hardev Pandha  is a clinician scientist and medical oncologist who graduated in medicine at the University of Birmingham. He trained in internal medicine and subsequently in medical oncology at the Royal Postgraduate Medical School at Hammersmith Hospital, London.  He completed his PhD (Imperial College) in the Imperial Cancer Research Fund labs at the Hammersmith. He was a visiting fellow at Stanford University prior to completing his medical oncology training at the Royal Marsden Hospital, London. He was a senior lecturer in tumour immunology and medical oncology at St Georges, University of London in 2000 before being appointed Prof of Urological Oncology at the University of Surrey in 2006.

His areas of expertise include the management of patients with Urological cancers and malignant melanoma. He has a key interest in early phase clinical trials involving targeted agents and the translational aspects of novel therapies. His portfolio includes gene and viral therapy as well as immunotherapy and small molecule inhibitors. His laboratory interests reflect this and in particular a combination of novel and biological therapies with more conventional treatments. His lab team have evolved a robust infrastructure of patient sample procurement and biobanking for translational research.

Research Interests

Tumour Immunology

Urological Cancer

Gene Therapy

For further information, please visit our Cancer Research theme page.

Publications

Journal articles

  • Adair RA, Scott KJ, Fraser S, Errington-Mais F, Selby P, Cook GP, Vile R, Toogood G, Melcher AA, Pandha H, Coffey M, Harrington KJ. (2013) 'Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells'. International Journal of Cancer, 132 (10), pp. 2327-2338.
  • McGrath SE, Michael A, Pandha H, Morgan R. (2013) 'Engrailed homeobox transcription factors as potential markers and targets in cancer.'. FEBS Lett, Netherlands: 587 (6), pp. 549-554.
  • McGrath SE, Michael A, Pandha H, Morgan R. (2013) 'Engrailed homeobox transcription factors as potential markers and targets in cancer'. FEBS Letters, 587 (6), pp. 549-554.
  • Mackenzie Ross AD, Hossain M, Bennett DC, Cook MG, Chong H, Pandha HS. (2013) 'Senescence evasion in melanoma progression: Uncoupling of DNA-damage signaling from p53 activation and p21 expression'. Pigment Cell and Melanoma Research, 26 (2), pp. 226-235.
  • Michael A, Relph K, Annels N, Pandha H. (2013) 'Prostate cancer vaccines.'. Expert Rev Vaccines, England: 12 (3), pp. 253-262.

    Abstract

    In 2010, the US FDA approved the first therapeutic cancer vaccine for the treatment of castration refractory prostate cancer - sipuleucel-T. Prostate cancer is an ideal model for cancer vaccine development based on the ready demonstration of humoral and cellular immunity to a range of cancer antigens as well as often slow progression which means that patients who are otherwise well may have a radiologically evaluable minor progression, after conventional treatment and can undergo vaccine therapy over sufficient periods of time, so as to allow the generation of a robust antitumor response. The association of prostate cancer with one of the few serum cancer biomarkers in general use has also allowed assessment of response and risk stratification of patients. In this review, we will examine key aspects of the evolution of prostate cancer vaccines, which provides an accurate prototype for other cancers, and the challenges we face.

  • Morgan R, Bryan RT, Javed S, Launchbury F, Zeegers MP, Cheng KK, James ND, Wallace DM, Hurst CD, Ward DG, Knowles MA, Pandha H. (2013) 'Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker.'. Elsevier Eur J Cancer,

    Abstract

    Despite significant advances in our understanding of the molecular pathology of bladder cancer, it remains a significant health problem with high morbidity and mortality associated with muscle-invasive bladder cancer (stages T2+), and high costs associated with the surveillance of non-muscle-invasive bladder cancer (NMIBC, stages Ta/T1/Tis). Moreover, current diagnostic biomarkers are suboptimal and of poor utility for low grade disease and surveillance. In this study, we show that the Engrailed-2 (EN2) transcription factor is expressed in, and secreted by, bladder cancer cell lines and patient tumour specimens, justifying an evaluation of urinary EN2 as a diagnostic biomarker in bladder cancer using archived samples from an established biospecimen collection. In patients with NMIBC, urinary EN2 was detected in most cases with an overall sensitivity of 82% and specificity of 75%. The sensitivity for stage Ta and T1 tumours was 71% and 76%, respectively, and 94% for stage T2+ tumours. This compares favourably with existing markers. The sensitivity for tumour grades 1, 2 and 3 was 69%, 78% and 87%, respectively. Thus urinary EN2 has the potential to be a more sensitive and specific protein biomarker for NMIBC than currently available tests.

  • Mansfield D, Pencavel T, Kyula JN, Zaidi S, Roulstone V, Karapanagiotou L, Khan AA, McLaughlin M, Touchefeu Y, Seth R, Harrington KJ, Thway K, Melcher AA, Vile RG, Pandha HS. (2013) 'Oncolytic Vaccinia virus and radiotherapy in head and neck cancer'. Oral Oncology, 49 (2), pp. 108-118.
  • Donnelly OG, Errington-Mais F, Steele L, Jennings V, Scott K, Bond J, Vile R, Selby P, Melcher AA, Hadac E, Russell S, Peach H, Phillips RM, Pandha H, Harrington K. (2013) 'Measles virus causes immunogenic cell death in human melanoma'. Gene Therapy, 20 (1), pp. 7-15.
  • Mackenzie Ross AD, Hossain M, Bennett DC, Cook MG, Chong H, Pandha HS. (2013) 'Senescence evasion in melanoma progression: Uncoupling of DNA-damage signaling from p53 activation and p21 expression'. Pigment Cell and Melanoma Research,
  • Alharbi RA, Pettengell R, Pandha HS, Morgan R. (2012) 'The role of HOX genes in normal hematopoiesis and acute leukemia.'. Nature Publishing Group Leukemia,

    Abstract

    The HOX genes are a highly conserved family of homeodomain-containing transcription factors that specify cell identity in early development and, subsequently, in a number of adult processes including hematopoiesis. The dysregulation of HOX genes is associated with a number of malignancies including acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), where they have been shown to support the immortalization of leukemic cells both as chimeric partners in fusion genes and when overexpressed in their wild type form. This review covers our current understanding of the role of HOX genes in normal hematopoiesis, AML and ALL, with particular emphasis on the similarities and differences of HOX function in these contexts, their hematopoietic downstream genes targets and implications for therapy.Leukemia accepted article preview online, 5 December 2012; doi:10.1038/leu.2012.356.

  • Adair RA, Scott KJ, Fraser S, Errington-Mais F, Pandha H, Coffey M, Selby P, Cook GP, Vile R, Harrington KJ, Toogood G, Melcher AA. (2012) 'Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells.'. Int J Cancer,
  • Morgan R, Boxall A, Harrington KJ, Simpson GR, Gillett C, Michael A, Pandha HS. (2012) 'Targeting the HOX/PBX dimer in breast cancer.'. Springer Breast Cancer Res Treat, Netherlands: 136 (2), pp. 389-398.
  • Morgan R, Boxall A, Simpson GR, Michael A, Pandha HS, Harrington KJ, Gillett C. (2012) 'Targeting the HOX/PBX dimer in breast cancer'. Breast Cancer Research and Treatment, 136 (2), pp. 389-398.
  • Pandha H, Sorensen KD, Orntoft TF, Langley S, Hoyer S, Borre M, Morgan R. (2012) 'Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer.'. Wiley-Blackwell BJU Int, England: 110 (6 Pt B), pp. E287-E292.
  • Pandha H, Morgan R, Sorensen KD, Orntoft TF, Borre M, Hoyer S, Langley S. (2012) 'Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer'. BJU International, 110 (6B)
  • Mansfield D, Pencavel T, Kyula JN, Zaidi S, Roulstone V, Thway K, Karapanagiotou L, Khan AA, McLaughlin M, Touchefeu Y, Seth R, Melcher AA, Vile RG, Pandha HS, Harrington KJ. (2012) 'Oncolytic Vaccinia virus and radiotherapy in head and neck cancer.'. Oral Oncol,
  • Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula JN, White C, McLaughlin M, Seth R, Karapanagiotou EM, Mansfield D, Coffey M, Nuovo G, Vile RG, Pandha HS, Melcher AA, Harrington KJ. (2012) 'Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.'. Gene Ther,
  • Donnelly O, Vile R, Pandha H, Harrington K, Melcher A. (2012) 'The hitchhiker's guide to virotherapy.'. Oncotarget, United States: 3 (8), pp. 735-736.
  • Tuan J, Pandha H, Corbishley C, Khoo V. (2012) 'Basaloid carcinoma of the prostate: A literature review with case report'. Indian Journal of Urology, 28 (3), pp. 322-324.
  • Adair RA, Roulstone V, Scott KJ, Morgan R, Nuovo GJ, Fuller M, Beirne D, West EJ, Jennings VA, Rose A, Kyula J, Fraser S, Dave R, Anthoney DA, Merrick A, Prestwich R, Aldouri A, Donnelly O, Pandha H, Coffey M, Selby P, Vile R, Toogood G, Harrington K, Melcher AA. (2012) 'Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.'. Sci Transl Med, United States: 4 (138)
  • Pulido J, Kottke T, Thompson J, Galivo F, Wongthida P, Diaz RM, Rommelfanger D, Ilett E, Pease L, Pandha H, Harrington K, Selby P, Melcher A, Vile R. (2012) 'Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma'. NATURE PUBLISHING GROUP NATURE BIOTECHNOLOGY, 30 (4), pp. 336-343.
  • Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ. (2012) 'Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.'. Clin Cancer Res, United States: 18 (7), pp. 2080-2089.
  • Simpson GR, Horvath A, Annels NE, Pencavel T, Metcalf S, Seth R, Peschard P, Price T, Coffin RS, Mostafid H, Melcher AA, Harrington KJ, Pandha HS. (2012) 'Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer'. BRITISH JOURNAL OF CANCER, 106 (3), pp. 496-507.
  • Hall K, Scott KJ, Rose A, Desborough M, Harrington K, Pandha H, Parrish C, Vile R, Coffey M, Bowen D, Errington-Mais F, Melcher AA. (2012) 'Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.'. Biores Open Access, United States: 1 (1), pp. 3-15.
  • Middleton GW, Annels NE, Pandha HS. (2012) 'Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?'. Cancer Immunol Immunother, Germany: 61 (1), pp. 1-7.
  • Twigger K, Roulstone V, Kyula J, Karapanagiotou EM, Syrigos KN, Morgan R, White C, Bhide S, Nuovo G, Coffey M, Thompson B, Jebar A, Errington F, Melcher AA, Vile RG, Pandha HS, Harrington KJ. (2012) 'Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.'. BMC Cancer, England: 12
  • Pulido J, Kottke T, Thompson J, Galivo F, Diaz RM, Rommelfanger D, Ilett E, Vile R, Wongthida P, Selby P, Melcher A, Pease L, Pandha H, Harrington K. (2012) 'Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma'. Nature Biotechnology, 30 (4), pp. 337-343.
  • Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, Peach H, Phillips RM, Bond J, Pandha H, Harrington K, Vile R, Russell S, Selby P, Melcher AA. (2011) 'Measles virus causes immunogenic cell death in human melanoma.'. Gene Ther,
  • Metcalf S, Pandha HS, Morgan R. (2011) 'Antiangiogenic effects of zoledronate on cancer neovasculature.'. Future Oncol, England: 7 (11), pp. 1325-1333.
  • Kottke T, Chester J, Ilett E, Thompson J, Diaz R, Coffey M, Selby P, Nuovo G, Pulido J, Mukhopadhyay D. (2011) 'Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy.'. Mol Ther, United States: 19 (10), pp. 1802-1812.
  • Donnelly OG, Errington-Mais F, Prestwich R, Harrington K, Pandha H, Vile R, Melcher AA. (2011) 'Recent Clinical Experience With Oncolytic Viruses.'. Curr Pharm Biotechnol,
  • Hamdan S, Verbeke CS, Fox N, Booth J, Bottley G, Pandha HS, Blair GE. (2011) 'The roles of cell surface attachment molecules and coagulation Factor X in adenovirus 5-mediated gene transfer in pancreatic cancer cells.'. Cancer Gene Ther, England: 18 (7), pp. 478-488.
  • Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P, Diaz RM, Chong H, Ilett E, Chester J, Pandha H, Harrington K, Selby P, Melcher A, Vile R. (2011) 'Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors.'. Nat Med, United States: 17 (7), pp. 854-859.
  • Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. (2011) 'Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.'. Cancer Immunol Immunother,
  • Ilett EJ, Bárcena M, Errington-Mais F, Griffin S, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Limpens RW, Mommaas M, Hoeben RC, Vile RG, Melcher AA. (2011) 'Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.'. Clin Cancer Res, United States: 17 (9), pp. 2767-2776.
  • Morgan R, Boxall A, Bhatt A, Bailey M, Hindley R, Langley S, Whitaker HC, Neal DE, Ismail M, Whitaker H, Annels N, Michael A, Pandha H. (2011) 'Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 17 (5), pp. 1090-1098.
  • Kelly ZL, Michael A, Butler-Manuel S, Pandha HS, Morgan RG. (2011) 'HOX genes in ovarian cancer.'. J Ovarian Res, England: 4
  • Middleton GW, Annels NE, Pandha HS. (2011) 'Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?'. Cancer Immunology, Immunotherapy, , pp. 1-7.
  • Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. (2011) 'Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13'. Cancer Immunology, Immunotherapy, 60 (10), pp. 1419-1430.
  • Steele L, Errington F, Prestwich R, Ilett E, Harrington K, Pandha H, Coffey M, Selby P, Vile R, Melcher A. (2011) 'Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-kappa B mediated and supports innate and adaptive anti-tumour immune priming'. BIOMED CENTRAL LTD MOLECULAR CANCER, 10 Article number ARTN 20
  • Kottke T, Ilett E, Thompson J, Diaz R, Vile R, Chester J, Selby P, Melcher A, Coffey M, Nuovo G, Pulido J, Mukhopadhyay D, Pandha H, Harrington K. (2011) 'Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy'. Molecular Therapy, 19 (10), pp. 1802-1812.
  • Gray S, Pandha HS, Michael A, Middleton G, Morgan R. (2011) 'HOX genes in pancreatic development and cancer.'. JOP, Italy: 12 (3), pp. 216-219.
  • Heinemann L, Simpson GR, Boxall A, Kottke T, Relph KL, Vile R, Melcher A, Prestwich R, Harrington KJ, Morgan R, Pandha HS. (2011) 'Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.'. Biomed Central BMC Cancer, England: 11

    Abstract

    Reovirus type 3 Dearing (T3D) has demonstrated oncolytic activity in vitro, in in vivo murine models and in early clinical trials. However the true potential of oncolytic viruses may only be realized fully in combination with other modalities such as chemotherapy, targeted therapy and radiotherapy. In this study, we examine the oncolytic activity of reovirus T3D and chemotherapeutic agents against human prostate cancer cell lines, with particular focus on the highly metastatic cell line PC3 and the chemotherapeutic agent docetaxel. Docetaxel is the standard of care for metastatic prostate cancer and acts by disrupting the normal process of microtubule assembly and disassembly. Reoviruses have been shown to associate with microtubules and may require this association for efficient viral replication.

  • Kelly ZL, Michael A, Butler-Manuel S, Pandha HS, Morgan RG. (2011) 'HOX genes in ovarian cancer'. Springer Journal of Ovarian Research, 4 (1)

    Abstract

    The HOX genes are a family of homeodomain-containing transcription factors that determine cellular identity during development. Here we review a number of recent studies showing that HOX genes are strongly expressed in ovarian cancer, and that in some cases the expression of specific HOX genes is sufficient to confer a particular identity and phenotype upon cancer cells. We also review the recent advances in elucidating the different functions of HOX genes in ovarian cancer. A literature search was performed using the search terms HOX genes (including specific HOX genes), ovarian cancer and oncogenesis. Articles were accessed through searches performed in ISI Web of Knowledge, PubMed and ScienceDirect. Taken together, these studies have shown that HOX genes play a role in the oncogenesis of ovarian cancer and function in the inhibition of apoptosis, DNA repair and enhanced cell motility. The function of HOX genes in ovarian cancer oncogenesis supports their potential role as prognostic and diagnostic markers, and as therapeutic targets in this disease.

  • Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Mettinger KL, Nuovo G, Cohn DE, Phelps M, Harrington KJ, Pandha HS. (2010) 'REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 16 (22), pp. 5564-5572.
  • Roberts A, Serrano M, Binda E, Vantourout P, Pandha H, Hayday AC. (2010) 'Expansion of Autologous Human V gamma 9V delta 2 T Cells Ex Vivo: Potential for Adoptive T Cell Therapy of Prostate Cancer'. LIPPINCOTT WILLIAMS & WILKINS J IMMUNOTHER, 33 (8), pp. 864-864.
  • Annels NE, Gabitass RF, Pandha H, Middleton GW. (2010) 'Elevated MDSCs in Pancreatic and Esophago-gastric Cancer Patients Correlates with Poor Prognosis'. LIPPINCOTT WILLIAMS & WILKINS J IMMUNOTHER, 33 (8), pp. 897-897.
  • Annels NE, Denyer M, Pandha H. (2010) 'Increased Myeloid Derived Suppressor Cells in Advanced Prostate Cancer'. LIPPINCOTT WILLIAMS & WILKINS J IMMUNOTHER, 33 (8), pp. 890-891.
  • Ismail M, Morgan R, Harrington K, Davies J, Pandha H. (2010) 'Immunoregulatory effects of freeze injured whole tumour cells on human dendritic cells using an in vitro cryotherapy model'. ACADEMIC PRESS INC ELSEVIER SCIENCE CRYOBIOLOGY, 61 (3), pp. 268-274.
  • Heinemann L, Simpson GR, Annels NE, Vile R, Melcher A, Prestwich R, Harrington KJ, Pandha HS. (2010) 'The Effect of Cell Cycle Synchronization on Tumor Sensitivity to Reovirus Oncolysis'. NATURE PUBLISHING GROUP MOLECULAR THERAPY, 18 (12), pp. 2085-2093.
  • Anesti A-M, Simpson GR, Price T, Pandha HS, Coffin RS. (2010) 'Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo'. BIOMED CENTRAL LTD BMC CANCER, 10 Article number ARTN 486
  • Lunt C, Barber N, Montgomery A, Kalsi V, Parker T, Michael A, Pandha H, Hindley R. (2010) 'CYTOREDUCTIVE NEPHRECTOMY IN THE TYROKINASE INHIBITOR ERA'. MARY ANN LIEBERT INC J ENDOUROL, 24, pp. A303-A303.
  • Michael A, Relph K, Pandha H. (2010) 'Emergence of potential biomarkers of response to anti-angiogenic anti-tumour agents'. WILEY-BLACKWELL INTERNATIONAL JOURNAL OF CANCER, 127 (6), pp. 1251-1258.
  • Pencavel T, Seth R, Hayes A, Melcher A, Pandha H, Vile R, Harrington KJ. (2010) 'Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?'. NATURE PUBLISHING GROUP GENE THERAPY, 17 (8), pp. 949-960.
  • Hingorani M, White CL, Zaidi S, Pandha HS, Melcher AA, Bhide SA, Nutting CM, Syrigos KN, Vile RG, Vassaux G, Harrington KJ. (2010) 'Therapeutic Effect of Sodium Iodide Symporter Gene Therapy Combined With External Beam Radiotherapy and Targeted Drugs That Inhibit DNA Repair'. NATURE PUBLISHING GROUP MOLECULAR THERAPY, 18 (9), pp. 1599-1605.
  • Daniels TR, Neacato II, Rodriguez JA, Pandha HS, Morgan R, Penichet ML. (2010) 'Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells'. NATURE PUBLISHING GROUP LEUKEMIA, 24 (9), pp. 1555-1565.
  • Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, Beirne D, Prestwich R, Newbold K, Ahmed M, Thway K, Nutting CM, Coffey M, Harris D, Vile RG, Pandha HS, DeBono JS, Melcher AA. (2010) 'Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 16 (11), pp. 3067-3077.
  • Kottke T, Hall G, Pulido J, Diaz RM, Thompson J, Chong H, Selby P, Coffey M, Pandha H, Chester J, Melcher A, Harrington K, Vile R. (2010) 'Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice'. AMER SOC CLINICAL INVESTIGATION INC JOURNAL OF CLINICAL INVESTIGATION, 120 (5), pp. 1551-1560.
  • Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS. (2010) 'Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics'. ELSEVIER SCI LTD CYTOKINE & GROWTH FACTOR REVIEWS, 21 (2-3), pp. 91-98.
  • John J, Ismail M, Riley C, Askham J, Morgan R, Melcher A, Pandha H. (2010) 'Differential effects of Paclitaxel on dendritic cell function'. BIOMED CENTRAL LTD BMC IMMUNOLOGY, 11 Article number ARTN 14
  • Morgan R, Plowright L, Harrington KJ, Michael A, Pandha HS. (2010) 'Targeting HOX and PBX transcription factors in ovarian cancer'. BIOMED CENTRAL LTD BMC CANCER, 10 Article number ARTN 89
  • Hingorani M, Spitzweg C, Vassaux G, Newbold K, Melcher A, Pandha H, Vile R, Harrington K. (2010) 'The Biology of the Sodium Iodide Symporter and its Potential for Targeted Gene Delivery'. BENTHAM SCIENCE PUBL LTD CURR CANCER DRUG TAR, 10 (2), pp. 242-267.
  • Michael A, John J, Meyer B, Pandha H. (2010) 'Activation and Genetic Modification of Human Monocyte-Derived Dendritic Cells using Attenuated Salmonella typhimurium'. THESCIENTIFICWORLD LTD THESCIENTIFICWORLDJOURNAL, 10, pp. 393-401.
  • Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F, Coffey M, Harrington KJ, Morgan R. (2009) 'Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 15 (19), pp. 6158-6166.
  • Ismail M, Morgan R, Harrington K, Davies J, Pandha H. (2009) 'Enhancing prostate cancer cryotherapy using tumour necrosis factor related apoptosis-inducing ligand (TRAIL) sensitisation in an in vitro cryotherapy model'. ACADEMIC PRESS INC ELSEVIER SCIENCE CRYOBIOLOGY, 59 (2), pp. 207-213.
  • Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, Vile RG. (2009) 'The Case of Oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon'. MARY ANN LIEBERT INC HUMAN GENE THERAPY, 20 (10), pp. 1119-1132.
  • Prestwich RJ, Errington F, Steele LP, Ilett EJ, Morgan RSM, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA. (2009) 'Reciprocal Human Dendritic Cell-Natural Killer Cell Interactions Induce Antitumor Activity Following Tumor Cell Infection by Oncolytic Reovirus'. AMER ASSOC IMMUNOLOGISTS JOURNAL OF IMMUNOLOGY, 183 (7), pp. 4312-4321.
  • Derhovanessian E, Adams V, Haehnel K, Groeger A, Pandha H, Ward S, Pawelec G. (2009) 'Pretreatment frequency of circulating IL-17(+)CD4(+) T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients'. WILEY-BLACKWELL INTERNATIONAL JOURNAL OF CANCER, 125 (6), pp. 1372-1379.
  • Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, Thompson J, Galivo F, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA. (2009) 'Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 15 (13), pp. 4374-4381.
  • Ismail M, Bokaee S, Davies J, Harrington KJ, Pandha H. (2009) 'Inhibition of the aquaporin 3 water channel increases the sensitivity of prostate cancer cells to cryotherapy'. NATURE PUBLISHING GROUP BRITISH JOURNAL OF CANCER, 100 (12), pp. 1889-1895.
  • Pandha H, Melcher A, Harrington K, Vile R. (2009) 'Oncolytic Viruses: Time to Compare, Contrast, and Combine?'. NATURE PUBLISHING GROUP MOLECULAR THERAPY, 17 (6), pp. 934-935.
  • Pandha H, D'Ambrosio C, Heenan S, Hyde N, Di Palma S, Nutting C, Relph K, Harrington K. (2009) 'Indium-labelled Autologous Dendritic Cells Migrate to Local Lymph Nodes after Intratumoural Injection in Head and Neck Cancer Patients'. ELSEVIER SCIENCE LONDON CLINICAL ONCOLOGY, 21 (4), pp. 363-364.
  • Ilett EJ, Prestwich RJ, Kottke T, Errington F, Thompson JM, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Vile RG, Melcher AA. (2009) 'Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity'. NATURE PUBLISHING GROUP GENE THERAPY, 16 (5), pp. 689-699.
  • Horvath A, Simpson GR, Coffin RS, Mostafid H, Pandha H. (2009) 'NOVEL INTRAVESICAL THERAPY FOR NON MUSCLE INVASIVE BLADDER CANCER: COMBINATION OF A FUSOGENIC GLYCOPROTEIN, PRO-DRUG ACTIVATION AND ONCOLYTIC HERPES SIMPLEX VIRUS'. ELSEVIER SCIENCE BV EUR UROL SUPPL, 8 (4), pp. 196-196.
  • Michael A, Syrigos K, Pandha H. (2009) 'Prostate cancer chemotherapy in the era of targeted therapy'. NATURE PUBLISHING GROUP PROSTATE CANCER AND PROSTATIC DISEASES, 12 (1), pp. 13-16.
  • Prestwich RJ, Scott KJ, Brown J, Harnden P, Whelan P, Cartledge J, O'Donnell D, Pandha HS, Selby PJ, Banks RE, Merrick AE, Melcher AA. (2009) 'The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma'. WILEY-BLACKWELL PUBLISHING, INC BJU INTERNATIONAL, 103 (6), pp. 740-746.
  • Plowright L, Harrington KJ, Pandha HS, Morgan R. (2009) 'HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer)'. NATURE PUBLISHING GROUP BRITISH JOURNAL OF CANCER, 100 (3), pp. 470-475.
  • Agrawal VK, Copeland KM, Barbachano Y, Rahim A, Seth R, White CL, Hingorani M, Nutting CM, Kelly M, Harris P, Pandha H, Melcher AA, Vile RG, Porter C, Harrington KJ. (2009) 'Microvascular free tissue transfer for gene delivery: in vivo evaluation of different routes of plasmid and adenoviral delivery'. NATURE PUBLISHING GROUP GENE THERAPY, 16 (1), pp. 78-92.
  • Pandha H, Melcher A, Vile R, Harrington K. (2009) '5th international meeting on replicating oncolytic virus therapeutics Banff, Alberta, Canada, 18-22 March 2009'. Molecular Therapy, 17 (6), pp. 934-935.
  • Koropouli E, Manolopoulus L, Pandha H, Syrigos KN. (2009) 'The biological role of mTOR in the pathogenesis of solid tumors: An overview'. Current Enzyme Inhibition, 5 (1), pp. 51-65.
  • Hingorani M, White CL, Merron A, Peerlinck I, Gore ME, Slade A, Scott SD, Nutting CM, Pandha HS, Melcher AA, Vile RG, Vassaux G, Harrington KJ. (2008) 'Inhibition of Repair of Radiation-Induced DNA Damage Enhances Gene Expression from Replication-Defective Adenoviral Vectors'. AMER ASSOC CANCER RESEARCH CANCER RESEARCH, 68 (23), pp. 9771-9778.
  • Yap TA, Brunetto A, Pandha H, Harrington K, de Bono JS. (2008) 'Reovirus therapy in cancer: has the orphan virus found a home?'. INFORMA HEALTHCARE EXPERT OPINION ON INVESTIGATIONAL DRUGS, 17 (12), pp. 1925-1935.
  • Prestwich RJ, Errington F, Ilett EJ, Morgan RSM, Scott KJ, Kottke T, Thompson J, Morrison EE, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA. (2008) 'Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 14 (22), pp. 7358-7366.
  • Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, Melcher A, Coffey M, Harrington KJ, DeBono JS. (2008) 'A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 14 (21), pp. 7127-7137.
  • Alamara C, Karapanagiotou EM, Tourkantonis I, Xyla V, Maurer CC, Lykourinas M, Pandha H, Syrigos KN. (2008) 'Renal oncocytoma: a case report and short review of the literature.'. Eur J Intern Med, Netherlands: 19 (7), pp. e67-e69.
  • Shears L, Plowright L, Harrington K, Pandha HS, Morgan R. (2008) 'Disrupting the Interaction Between HOX and PBX Causes Necrotic and Apoptotic Cell Death in the Renal Cancer Lines CaKi-2 and 769-P'. ELSEVIER SCIENCE INC JOURNAL OF UROLOGY, 180 (5), pp. 2196-2201.
  • Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. (2008) 'Oncolytic viruses: a novel form of immunotherapy'. EXPERT REVIEWS EXPERT REVIEW OF ANTICANCER THERAPY, 8 (10), pp. 1581-1588.
  • Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, Ilett LJ, Prestwich R, Pandha HS, Coffey M, Selby P, Vile R, Harrington KJ, Melcher AA. (2008) 'Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma'. NATURE PUBLISHING GROUP GENE THERAPY, 15 (18), pp. 1257-1270.
  • Comins C, Heinemann L, Harrington K, Melcher A, De Bono J, Pandha H. (2008) 'Reovirus: Viral therapy for cancer 'as nature intended''. ELSEVIER SCIENCE LONDON CLINICAL ONCOLOGY, 20 (7), pp. 548-554.
  • Hingorani M, White CL, Zaidi S, Merron A, Peerlinck I, Gore ME, Nutting CM, Pandha HS, Melcher AA, Vile RG, Vassaux G, Harrington KJ. (2008) 'Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: Implications for sodium iodide symporter gene therapy'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 14 (15), pp. 4915-4924.
  • Harrington KJ, Melcher A, Vassaux G, Pandha HS, Vile RG. (2008) 'Exploiting synergies between radiation and oncolytic viruses'. THOMSON SCIENTIFIC CURRENT OPINION IN MOLECULAR THERAPEUTICS, 10 (4), pp. 362-370.
  • White CL, Twigger KR, Vidal L, De Bono JS, Coffey M, Heinemann L, Morgan R, Merrick A, Errington F, Vile RG, Melcher AA, Pandha HS, Harrington KJ. (2008) 'Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial'. NATURE PUBLISHING GROUP GENE THERAPY, 15 (12), pp. 911-920.
  • Pandha HS, Protheroe A, Wylie J, Parker C, Chambers J, Bell S, Munzert G. (2008) 'An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC)'. AMER SOC CLINICAL ONCOLOGY JOURNAL OF CLINICAL ONCOLOGY, 26 (15)
  • Havranek EG, Labarthe M-C, Ward S, Anderson CJ, Whelan MA, Pandha H. (2008) 'A novel murine model of allogeneic vaccination against renal cancer'. BLACKWELL PUBLISHING BJU INTERNATIONAL, 101 (9), pp. 1165-1169.
  • Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L, de Bono J, Selby P, Coffey M, Vile R, Melcher A. (2008) 'Reovirus activates human dendritic cells to promote innate antitumor immunity'. AMER ASSOC IMMUNOLOGISTS JOURNAL OF IMMUNOLOGY, 180 (9), pp. 6018-6026.
  • White CL, Menghistu T, Twigger KR, Searle PF, Bhide SA, Vile RG, Melcher AA, Pandha HS, Harrington KJ. (2008) 'Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo'. NATURE PUBLISHING GROUP GENE THERAPY, 15 (6), pp. 424-433.
  • Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, Thompson B, Vile RG, Heinemann L, Pandha HS, Errington F, Melcher AA, Harrington KJ. (2008) 'Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 14 (3), pp. 912-923.
  • Gore ME, Nutting CM, Pandha HS, Melcher AA, Vile RG, Harrington KJ. (2008) 'T-cell responses to survivin in cancer patients undergoing radiation therapy'. Clinical Cancer Research, 14 (15), pp. 4883-4883.
  • Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM, Thompson J, Selby P, de Bono J, Melcher A, Pandha H, Coffey M, Vile R, Harrington K. (2008) 'Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 14 (1), pp. 259-269.
  • Prestwich RJ, Errington F, Harrington KJ, Pandha HS, Selby P, Melcher A. (2008) 'Oncolytic viruses: do they have a role in anti-cancer therapy?'. Clin Med Oncol, New Zealand: 2, pp. 83-96.
  • Papaetis GS, Karapanagiotou LM, Pandha H, Syrigos KN. (2008) 'Targeted therapy for advanced renal cell cancer: Cytokines and beyond'. BENTHAM SCIENCE PUBL LTD CURRENT PHARMACEUTICAL DESIGN, 14 (22), pp. 2229-2251.
  • Plowright L, Shears L, Pandha H, Morgan R. (2007) 'Disrupting the interaction between Hox and PBX causes apoptotic cell death and reduces in vivo proliferation of a non-small cell lung cancer model'. AMER ASSOC CANCER RESEARCH MOLECULAR CANCER THERAPEUTICS, 6 (12), pp. 3504S-3504S.
  • Harris D, Vidal L, Melcher A, Newbold K, Anthony A, Karavasilis V, Agarwal R, White C, Twigger K, Coffey M, Mettinger K, Thompson B, Pandha H, De-Bono J, Harrington K. (2007) 'A Phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type Reovirus (REOLYSIN (R)) in combination with radiation in patients with advanced malignancies.'. AMER ASSOC CANCER RESEARCH MOLECULAR CANCER THERAPEUTICS, 6 (12), pp. 3458S-3458S.
  • Michael A, Politi E, Havranek E, Corbishley C, Karapanagiotou L, Anderson C, Relph K, Syrigos KN, Pandha H. (2007) 'Prognostic significance of erythropoietin expression in human renal cell carcinoma'. BLACKWELL PUBLISHING BJU INTERNATIONAL, 100 (2), pp. 291-294.
  • Morgan R, Pirard PM, Shears L, Sohal J, Pettengell R, Pandha HS. (2007) 'Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma'. AMER ASSOC CANCER RESEARCH CANCER RESEARCH, 67 (12), pp. 5806-5813.
  • Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, Pandha H. (2007) 'Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: A phase II study'. ELSEVIER SCIENCE INC JOURNAL OF UROLOGY, 177 (6), pp. 2136-2140.
  • Pandha H, Rigg A, John J, Lemoine N. (2007) 'Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines'. BLACKWELL PUBLISHING CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 148 (1), pp. 127-135.
  • Dalgleish A, Pandha H, Hampton GM, Sikora K. (2007) 'Tumor antigens as surrogate markers and targets for therapy and vaccines'. ELSEVIER ACADEMIC PRESS INC ADVANCES IN CANCER RESEARCH, VOL 96, 96, pp. 175-190.
  • Hu JCC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I, Medley LC, Michael A, Nutting CM, Pandha HS, Shorrock CA, Simpson J, Steiner J, Steven NM, Wright D, Coombes RC. (2006) 'A phase I study of OncoVEX(GM-CSF), a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 12 (22), pp. 6737-6747.
  • Pandha H, Birchall L, Meyer B, Wilson N, Relph K, Anderson C, Harrington K. (2006) 'Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines'. ELSEVIER SCIENCE INC JOURNAL OF UROLOGY, 176 (5), pp. 2255-2261.
  • Morgan R, Fairfax B, Pandha HS. (2006) 'Calcium insensitivity of FA-6, a cell line derived from a pancreatic cancer associated with humoral hypercalcemia, is mediated by the significantly reduced expression of the Calcium Sensitive Receptor transduction component p38 MAPK'. BIOMED CENTRAL LTD MOLECULAR CANCER, 5 Article number ARTN 51
  • Yap TA, Vidal L, Pandha H, Spicer J, Digue L, Coffey M, Thompson B, Kaye SB, Harrington KJ, De-Bono JS. (2006) 'A phase I study of wild-type reovirus, which selectively replicates in cells expressing activated Ras, administered intravenously to patients with advanced cancer'. PERGAMON-ELSEVIER SCIENCE LTD EJC SUPPLEMENTS, 4 (12), pp. 108-108.
  • Chowdhury S, Pandha H. (2006) 'Targeting renal cell carcinoma'. ELSEVIER SCIENCE LONDON CLINICAL ONCOLOGY, 18 (7), pp. 511-512.
  • Quatan N, Meyer B, Bailey M, Pandha H. (2006) 'Persistently high levels of immunosuppressive cytokines in patients after radical prostatectomy'. NATURE PUBLISHING GROUP PROSTATE CANCER AND PROSTATIC DISEASES, 9 (4), pp. 420-425.
  • Spicer J, Plunkett T, Somaiah N, Chan S, Kendall A, Bolunwu N, Pandha H. (2005) 'Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer'. NATURE PUBLISHING GROUP PROSTATE CANCER AND PROSTATIC DISEASES, 8 (4), pp. 364-368.

Conference papers

  • Annels NE, Simpson GR, Bokaee S, Riley C, Denyer M, Pandha H, Morgan R. (2012) 'Modulation of Regulatory T Cells by Targeting The NFAT-FOXP3 Protein: Protein Interaction'. LIPPINCOTT WILLIAMS & WILKINS JOURNAL OF IMMUNOTHERAPY, North Bethesda, MD: 27th Annual Scientific Meeting of the Society-for-Immunotherapy-of-Cancer (SITC) 35 (9), pp. 775-775.
  • Kelly Z, Pandha H, Morgan R, Michael A. (2012) 'HXR9 AND PARP INHIBITION -A NOVEL THERAPEUTIC IN OVARIAN CANCER'. OXFORD UNIV PRESS ANNALS OF ONCOLOGY, Vienna, AUSTRIA: 37th Congress of the European-Society-for-Medical-Oncology (ESMO) 23, pp. 325-325.
  • Ravaud A, Motzer RJ, Pandha H, Staehler M, George DJ, Pantuck A, Patel A, Gerletti P, Chen L, Patard J. (2012) 'SUNITINIB TREATMENT OF RENAL ADJUVANT CANCER (S-TRAC): A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF SUNITINIB VS. PLACEBO IN SUBJECTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC)'. OXFORD UNIV PRESS ANNALS OF ONCOLOGY, Vienna, AUSTRIA: 37th Congress of the European-Society-for-Medical-Oncology (ESMO) 23, pp. 292-293.
  • Kelly Z, Pandha H, Madhuri K, Morgan R, Michael A. (2012) 'HOX GENE EXPRESSION IN OVARIAN CANCER'. OXFORD UNIV PRESS ANNALS OF ONCOLOGY, Vienna, AUSTRIA: 37th Congress of the European-Society-for-Medical-Oncology (ESMO) 23, pp. 68-68.
  • Kottke T, Donnelly O, Boisgerault N, Diaz R, Thompson J, Chester J, Pandha H, Harrington K, Melcher A, Vile R. (2012) 'Characterization of the Mechanisms of Tumor Dormancy and Recurrence Following Front Line Immuno-, Viro- or Suicide Gene-, Therapy'. NATURE PUBLISHING GROUP MOLECULAR THERAPY, Philadelphia, PA: 15th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT) 20, pp. S268-S268.
  • Michael A, Riley, C, Bokaee S, Denyer M, Pandha H, Annels N. (2011) 'EN2: A candidate antigen for the development of targeted therapies in ovarian cancer.'. JCO, Chicago: ASCO (J Clin Oncol 29: 2011 (suppl; abstr e15528))
  • Horvath A, Simpson GR, Coffin RS, Mostafid AH, Pandha H. (2011) 'Update on a novel intravesical therapy for non muscle invasive bladder cancer: Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic herpes simplex virus'. WILEY-BLACKWELL BRITISH JOURNAL OF SURGERY, Royal Free Hosp, London, ENGLAND: Annual Meeting of the Society-of-Academic-and-Research-Surgeons 98 (6), pp. E2-E2.
  • Ismail MI, Bokaee S, Annels N, Davies J, Pandha H. (2011) 'Predominance of CD8 T cell infiltration coincides with reciprocal reduction in regulatory T cells following prostate cryotherapy'. WILEY-BLACKWELL BRITISH JOURNAL OF SURGERY, Royal Coll Surgery, Dublin, IRELAND: Annual Meeting of the Society-of-Academic-and-Research-Surgery 98, pp. 48-48.
  • Michael A, Zylstra J, Pandha H. (2011) 'The sun study-a biobank of sequential blood samples from patients with prostate cancer'. WILEY-BLACKWELL BRITISH JOURNAL OF SURGERY, Royal Coll Surgery, Dublin, IRELAND: Annual Meeting of the Society-of-Academic-and-Research-Surgery 98, pp. 50-50.
  • Binda E, Perez SM, Pandha H, Eberl M, Hayday A. (2010) 'Monitoring the immunological effects of bisphosphonates in different treatment scenarios'. WILEY-BLACKWELL PUBLISHING, INC IMMUNOLOGY, Liverpool, ENGLAND: Annual Congress of the British-Society-for-Immunology 131, pp. 117-117.
  • Roberts A, Serrano M, Vantourout P, Dieli F, Pandha H, Hayday AC. (2010) 'Expansion of autologous human V gamma 9V delta 2 T cells ex vivo: potential for adoptive T cell therapy of prostate cancer'. WILEY-BLACKWELL PUBLISHING, INC IMMUNOLOGY, Liverpool, ENGLAND: Annual Congress of the British-Society-for-Immunology 131, pp. 119-119.
  • Annels NE, Riley C, Bokaee S, Denyer M, Simpson GR, Pandha H. (2010) 'EN2: A Novel Immunotherapeutic Target for Melanoma'. LIPPINCOTT WILLIAMS & WILKINS JOURNAL OF IMMUNOTHERAPY, 33 (8), pp. 891-891.
  • Horvath A, Simpson GR, Coffin RS, Mostafid H, Pandha H. (2010) 'NOVEL INTRAVESICAL THERAPY FOR NON MUSCLE INVASIVE BLADDER CANCER USING A GENETICALLY MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS'. ELSEVIER SCIENCE BV EUROPEAN UROLOGY SUPPLEMENTS, 9 (6), pp. 646-646.
  • Ismail M, Morgan R, Davies J, Pandha H. (2009) 'Inhibition of the aquaporin water channels (AQPs) increases the sensitivity of DU145 cells to cryotherapy'. WILEY-BLACKWELL PUBLISHING, INC BJU INTERNATIONAL, Glasgow, SCOTLAND: Annual Meeting of the British-Association-of-Urological-Surgeons 103, pp. 21-21.
  • Rudman SM, Comins C, Mukherji D, Coffey M, Mettinger K, Protheroe A, Harrington KJ, Pandha H, Spicer JF. (2009) 'Results of a phase I study to evaluate the feasibility, safety, and biological effects of intravenous administration of wild-type reovirus with docetaxel to patients with advanced malignancies'. AMER SOC CLINICAL ONCOLOGY JOURNAL OF CLINICAL ONCOLOGY, Orlando, FL: 45th Annual Meeting of the American-Society-of-Clinical-Oncology 27 (15)
  • Karapanagiotou E, Pandha HS, Hall G, Chester J, Melcher A, Coffey M, de Bono J, Gore ME, Nutting CM, Harrington KJ. (2009) 'Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers'. AMER SOC CLINICAL ONCOLOGY JOURNAL OF CLINICAL ONCOLOGY, Orlando, FL: 45th Annual Meeting of the American-Society-of-Clinical-Oncology 27 (15)
  • Ismail M, Morgan R, Davies J, Pandha H. (2009) 'INHIBITION OF THE AQUAPORIN WATER CHANNELS INCREASES THE SENSITIVITY OF PROSTATE CANCER CELLS TO FREEZING INJURY.'. ELSEVIER SCIENCE INC JOURNAL OF UROLOGY, Chicago, IL: 104th Annual Meeting of the American-Urological-Association 181 (4), pp. 185-185.
  • Ismail M, Kevin H, Morgan R, Davies J, Pandha H. (2009) 'ENHANCING PROSTATE CANCER CRYOTHERAPY USING TUMOUR NECROSIS FACTOR RELATED APOPTOSIS-INDUCING LIGAND (TRAIL) SENSITISATION IN A NOVEL IN VITRO MODEL'. ELSEVIER SCIENCE INC JOURNAL OF UROLOGY, Chicago, IL: 104th Annual Meeting of the American-Urological-Association 181 (4), pp. 189-190.
  • Karapanagiotou E, Pandha H, Hall G, Chester J, Melcher A, De Bono J, Gore M, Nutting C, Harrington K. (2008) 'Phase I Trial of Oncolytic Reovirus (Reolysin) in Combination With Carboplatin/Paclitaxel in Patients With Advanced Solid Cancers'. LIPPINCOTT WILLIAMS & WILKINS JOURNAL OF IMMUNOTHERAPY, San Diego, CA: 23rd Annual Scientific Meeting of the International-Society-for-Biological-Therapy-of-Cancer 31 (9), pp. 952-952.
  • Comins C, Spicer J, Protheroe A, Mukherji D, Coffey M, Thompson B, Harrington K, Pandha H. (2008) 'A Phase I Study to Evaluate Systemic Wild-type Reovirus (REOLYSIN)(R) in Combination With Docetaxel in Patients With Advanced Malignancies'. LIPPINCOTT WILLIAMS & WILKINS JOURNAL OF IMMUNOTHERAPY, San Diego, CA: 23rd Annual Scientific Meeting of the International-Society-for-Biological-Therapy-of-Cancer 31 (9), pp. 951-951.
  • Heinemann L, Kottke T, Vile R, Coffey MC, Harrington K, Melcher A, Pandha HS. (2008) 'Synergistic Anti-Tumor Activity of Oncolytic Reovirus and Docetaxel in a PC-3 Prostate Cancer Mouse Model'. LIPPINCOTT WILLIAMS & WILKINS JOURNAL OF IMMUNOTHERAPY, San Diego, CA: 23rd Annual Scientific Meeting of the International-Society-for-Biological-Therapy-of-Cancer 31 (9), pp. 951-952.
  • Simpson GR, Horvath A, Harrington K, Coffin RS, Pandha H. (2008) 'Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer'. PERGAMON-ELSEVIER SCIENCE LTD EJC SUPPLEMENTS, Geneva, SWITZERLAND: 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 6 (12), pp. 97-98.
  • Heinemann L, Simpson G, Harrington K, Melcher A, Coffey MC, Pandha HS. (2008) 'Synergistic anti-tumour activity of oncolytic Reovirus and cisplatin in a B16.F10 mouse melanoma model'. PERGAMON-ELSEVIER SCIENCE LTD EJC SUPPLEMENTS, Geneva, SWITZERLAND: 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 6 (12), pp. 99-99.
  • Ismail M, Morgan R, Davies J, Pandha H. (2008) 'Immunoregulatory effects of cryo-treated prostate cancer cells on human dendritic cells using a novel in vitro cryotherapy model'. ELSEVIER SCIENCE INC JOURNAL OF UROLOGY, Orlando, FL: 103rd Annual Meeting of the American-Urological-Association 179 (4), pp. 48-48.
  • Meyer B, Denyer M, Morgan R, Pandha H. (2007) 'Cellular effects of phosphoramide mustard, the active metabolite of cyclophosphamide, on naturally-occuring human CD4(+) CD25(+) regulatory T cells'. LIPPINCOTT WILLIAMS & WILKINS JOURNAL OF IMMUNOTHERAPY, Boston, MA: 22nd Annual Scientific Meeting of the International-Society-for-Biological-Therapy-of-Cancer 30 (8), pp. 887-887.
  • Balls G, Quatan N, Michael A, Lancashire L, Adams V, Hoffman B, Pfirschke C, Russell N, Whelan M, Pandha H. (2007) 'Immunological response patterns correlate with clinical outcome after allogeneic vaccination in hormone resistant prostate cancer metastatic to bone'. LIPPINCOTT WILLIAMS & WILKINS JOURNAL OF IMMUNOTHERAPY, Boston, MA: 22nd Annual Scientific Meeting of the International-Society-for-Biological-Therapy-of-Cancer 30 (8), pp. 891-891.
  • Ismail M, Ahmed S, Laing R, Nigam R, Langley S, Pandha H, Davies J. (2007) 'Antibody immunity to prostate cancer specific antigen in the serum of patients having cryotherapy or brachytherapy treatment compared to healthy volunteers'. BLACKWELL PUBLISHING BJU INTERNATIONAL, Glasgow, SCOTLAND: Annual Meeting of the British-Association-of-Urological-Surgeons 99, pp. 47-48.
  • Verbeke CS, Hamdan S, Booth J, Pandha HS, Blair GE. (2006) 'Limited expression of the Coxsackie and Adenovirus Receptor in pancreatic cancer may reduce suitability of adenoviral gene therapy'. JOHN WILEY & SONS LTD JOURNAL OF PATHOLOGY, Manchester, ENGLAND: 190th Meeting of the Pathological-Society-of-Great-Britain-and-Ireland 210, pp. 2-2.
  • Vidal L, Pandha H, Spicer J, Harrington KJ, Allen S, Leader D, Coffey M, Thompson B, Kaye S, De-Bono J. (2006) 'A phase I study of reolysin given intravenously to patients with advanced malignancies.'. AMER SOC CLINICAL ONCOLOGY JOURNAL OF CLINICAL ONCOLOGY, Atlanta, GA: 42nd Annual Meeting of the American-Society-of-Clinical-Oncology 24 (18), pp. 136S-136S.
  • Vidal L, Pandha H, Harrington K, Fong P, Shaw H, Barrett M, Leader D, White C, Twigger K, Coffey M, Thompson B, Kaye S, De-Bono J. (2005) 'A phase I study of a wild-type reovirus (Reolysin) given intravenously to patients with advanced malignancies.'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, Philadelphia, PA: AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics 11 (24), pp. 9106S-9107S.
  • Vidal L, Twigger K, White C, Coffey M, Thompson B, De-Bono J, Pandha HS, Melcher A, Kaye S, Harrington KJ. (2005) 'Reovirus enhances radiation cytotoxicity in vitro and in vivo.'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, Philadelphia, PA: AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics 11 (24), pp. 9005S-9006S.

Books

  • Pandha HS, Relph K, Harrington K. (2008) Treatment of Cancer 5th Edition Chapter Gene Therapy. 5th Edition.
  • Pandha HS, Harrington KJ, Vile RG. (2008) Viral Therapy of Cancer. John Wiley

Book chapters

  • Pandha HS, Harrington KJ, Vile RG. (2008) 'Poxviruses as immunomodulatory cancer therapeutics.'. in (ed.) Viral Therapy of Cancer

 

8 Book Chapters

 

Methods Mol Biol. 2009;542:551-64. Simpson GR, Coffin RS. Construction and characterization of an oncolytic HSV vector containing a fusogenic glycoprotein and prodrug activation for enhanced local tumor control.

 

Treatment of Cancer 5th Edition 2008. Edited by Pat Price Karol Sikora and Timothy Illidge.

Chapter: Gene Therapy Kate Relph, Kevin Harrington, Hardev Pandha.

 

Viral Therapy of Cancer. Ed K.J. Harrington, H.S. Pandha and R.G. Vile. Publish by John Wiley Ltd.(ISBN 978-0-470-01922-1).

Chapter: Adenoviruses. Kate Relph,

 

Chapter: Oncolytic herpes simplex viruses. Guy R. Simpson and Robert S. Coffin

 

Chapter: Poxviruses as immunomodulatory cancer therapeutics. Kevin J Harrington, Hardev S Pandha and Richard G Vile.

 

Comprehensive Textbook of Prostate Cancer, edited by Dr. Tewari,

Chapter: Presentation and symptomatology of prostate cancer Dr A Michael

Chapter: Prostate Immunotherapy Dr Nicola Annels

 

Training in Oncology, Oncology and Paliative Care (Manuscript in preparation) Oxford University Press. Michael A and Pandha H

Page Owner: eih435
Page Created: Wednesday 4 January 2012 11:36:26 by pr0004
Last Modified: Monday 31 March 2014 10:17:25 by eih437
Expiry Date: Saturday 27 November 2010 15:58:24
Assembly date: Fri Apr 25 00:26:35 BST 2014
Content ID: 70751
Revision: 14
Community: 1196